عنوان

Inhalation drug delivery :

شابک

1118354125 (hardback)

شابک

9781118354124 (hardback)

شماره

dltt

عنوان اصلي

Inhalation drug delivery :

نام عام مواد

[Book]

ساير اطلاعات عنواني

techniques and products /

نام نخستين پديدآور

Paolo Colombo, Daniela Traini, Francesca Buttini

محل نشرو پخش و غیره

Hoboken, NY :

نام ناشر، پخش کننده و غيره

Wiley-Blackwell,

تاریخ نشرو بخش و غیره

2013

نام خاص و کميت اثر

xiv, 197 p. :

ساير جزييات

ill. ;

ابعاد

26 cm

عنوان فروست

ULLA postgraduate pharmacy series

متن يادداشت

Includes bibliographical references and index

متن يادداشت

1.Inhalation drug delivery / Daniela Traini -- 1.1.Introduction -- 1.2.Brief review of the respiratory system and its physiology -- 1.3.Deposition and the fate of particles in the respiratory tract -- 1.4.Deposition mechanisms -- 1.5.Parameters influencing particle deposition -- 1.6.The clearance of deposited particles -- 1.7.Airways geometry and humidity -- 1.8.Lung clearance mechanisms -- 1.9.Local and systemic drug delivery -- 1.10.Conclusion -- References -- 2.Inhalation and nasal products / Daniela Traini and Paul M. Young -- 2.1.Introduction -- 2.2.Dry powder inhalers (DPIs) -- 2.3.Liquid and propellant-based inhalers -- 2.3.1.Pressurized metered-dose inhalers (pMDIs) -- 2.3.2.Nebulizers -- 2.4.Nasal formulations -- 2.4.1.Nasal physiology -- 2.4.2.Delivery issues and concerns -- 2.4.3.Strategy for enhanced nasal delivery -- 2.4.4.Marketed nasal products -- 2.4.5.Pharmaceutical development studies for nasal products -- 2.5.Conclusion -- References --

متن يادداشت

3.Formulation of inhalation medicines / Daniela Traini and Paul M. Young -- 3.1.Introduction -- 3.2.Pressurized metered-dose inhaler (pMDI) formulation -- 3.2.1.Suspension technology -- 3.2.2.Solution technology -- 3.3.Dry powder inhaler (DPI) formulation -- 3.3.1.Carrier technology -- 3.3.2.Agglomerate technology -- 3.4.Conclusion -- References -- 4.Novel particle production technologies for inhalation products / Hak-Kim Chan and Philip Chi Lip Kwok -- 4.1.Introduction -- 4.2.Conventional crystallization and milling -- 4.3.Specialized milling -- 4.3.1.Fluid-energy milling at elevated humidity -- 4.3.2.Wet-milling nanotechnology -- 4.4.Solvent precipitation -- 4.4.1.Sono-crystallization -- 4.4.2.Microprecipitation by opposing liquid jets and tangential liquid jets -- 4.4.3.High-gravity controlled precipitation -- 4.5.Spray-drying and related droplet evaporation methods -- 4.5.1.Spray-drying -- 4.5.2.Controlled evaporation of droplets -- 4.5.3.Evaporation of low-boiling-point solutions --

متن يادداشت

4.5.4.Spray freeze-drying -- 4.6.Supercritical fluid (SCF) technology -- 4.7.Conclusion -- Acknowledgements -- References -- 5.Methods for understanding, controlling, predicting, and improving drug product performance / David A.V. Morton -- 5.1.Introduction -- 5.1.1.The complexities and challenges of aerosol performance -- 5.1.2.Understanding powder/particle characteristics: implications for aerosol product performance -- 5.1.3.Liquid systems -- 5.1.4.Summary -- 5.2.Particle sizing -- 5.2.1.Sieve analysis -- 5.2.2.Image analysis -- 5.2.3.Light scatter -- 5.2.4.Time-of-flight -- 5.2.5.Other methods -- 5.3.Powder and particulate characterization systems -- 5.3.1.Introduction -- 5.3.2.Powder cohesion and adhesion -- 5.3.3.Microscopic material characterization -- 5.3.4.Methods for studying bulk powders -- 5.4.Practical issues in process control -- 5.4.1.Common primary and secondary processing methods and issues arising for control --

متن يادداشت

5.5.Biopharmaceutical powder stability -- 5.6.Liquids: solutions and suspensions -- 5.6.1.Liquid formulation stability -- 5.7.Conclusion -- References -- 6.Aerodynamic assessment for inhalation products: fundamentals and current pharmacopoeial methods / Francesca Buttini, Gaia Colombo, Philip Chi Lip Kwok and Wong Tin Wui -- 6.1.Introduction -- 6.2.Impactor/impinger design -- 6.3.Aerodynamic assessment -- 6.4.Inertial impaction and cut-off diameter -- 6.5.Pharmacopoeial procedure -- 6.5.1.The duration of in vivo inspiration needed for 4L -- 6.5.2.Setting flow rate, Q, to give a pressure drop of 4 kPa -- 6.5.3.Flow-rate stability -- 6.6.Cascade impactor: general set-up and operation -- 6.7.Impactor/impinger characteristics -- 6.7.1.Twin-stage impinger (or glass impinger, apparatus A) -- 6.7.2.Multistage liquid impinger (MSLI) -- 6.7.3.Andersen cascade impactor (ACI) -- 6.7.4.Next-generation impactor (NGI) -- 6.8.Data analysis -- 6.9.Cleaning instructions for impactors -- 6.10.Test limitations --

متن يادداشت

6.11.Future considerations -- 6.11.1.Electrical low-pressure impactor (ELPI) -- References -- 7.Proteins, peptides, and controlled-release formulations for inhalation / Philip Chi Lip Kwok, Rania Osama Salama and Hak-Kim Chan -- 7.1.Proteins and peptides for inhalation -- 7.1.1.Stability of proteins -- 7.1.2.Nebulizers and the AERx pulmonary delivery system -- 7.1.3.Metered-dose inhalers (MDIs) -- 7.1.4.Dry powder inhalers (DPIs) -- 7.2.Controlled-release formulations for inhalation -- 7.2.1.Challenges facing controlled-release inhalation therapy -- 7.2.2.Production of inhalable controlled-release formulations -- References -- 8.Pharmaceutical development studies for inhalation products / Gaia Colombo, Chiara Parlati, and Paola Russo -- 8.1.Introduction -- 8.2.Pharmaceutical development studies for inhalation products -- 8.2.1.Studies demonstrating product performance with respect to formulation, delivery device, and their combination --

متن يادداشت

8.2.2.Studies demonstrating product performance in the hands of the patient (handling, use, storage) -- 8.2.3.Additional studies demonstrating specific development requirements -- 8.3.Conclusion -- Acknowledgements -- References -- 9.Quality of inhalation products: specifications / Paolo Colombo, Francesca Buttini, and Wong Tin Wui -- 9.1.Introduction -- 9.2.Inhalation-product specifications -- 9.2.1.Description -- 9.2.2.Identification -- 9.2.3.Drug content -- 9.2.4.Impurities and degradation products -- 9.2.5.Preservative content -- 9.2.6.Microbial limits -- 9.2.7.Sterility -- 9.2.8.Delivered-dose uniformity -- 9.2.9.Content uniformity/uniformity of dosage units -- 9.2.10.Mean delivered dose -- 9.2.11.Number of actuations per container -- 9.2.12.Fine-particle mass -- 9.2.13.Spray pattern and plume geometry -- 9.2.14.Leak rate -- 9.2.15.Moisture content -- 9.2.16.Leachables -- 9.2.17.pH -- 9.2.18.Osmolality -- 9.2.19.Extraneous particles -- 9.3.Additional quality aspects --

متن يادداشت

9.3.1.Drug substances -- 9.3.2.Excipients -- 9.3.3.Container closure systems -- 9.3.4.Inhalation-product stability -- 9.3.5.Package inserts and labels -- 9.3.6.Clinical/bioequivalence requirements -- References

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

بدون عنوان

0

متن يادداشت

"Provides students and those in industry with concise clear guide to the essential fundamentals in inhalation drug delivery"--Provided by publisher

موضوع مستند نشده

Aerosol therapy

موضوع مستند نشده

Inhalers

موضوع مستند نشده

Pharmaceutical technology

موضوع مستند نشده

Respiratory therapy

موضوع مستند نشده

Administration, Inhalation

موضوع مستند نشده

Drug Delivery Systems-- methods

شماره

ويراست

شماره رده

نشانه اثر

شماره رده

شماره رده

مستند نام اشخاص تاييد نشده

Colombo, Paolo,1944-

مستند نام اشخاص تاييد نشده

Buttini, Francesca

مستند نام اشخاص تاييد نشده

Traini, Daniela

تاريخ عمليات

20130619040613.0

نام الکترونيکي

نوع ماده

[Book]

تكميل شده

Y